Ajit Singh , PhD

Partner

Artiman Ventures
East Palo Alto, CA

Ajit Singh, Ph.D., is currently a partner at Artiman Ventures where he focuses on early-stage Technology and Life Sciences / Med-Tech investments. On behalf of Artiman, he serves on the Board of Directors of CardioDx Inc., OncoStem Diagnostics Pvt Ltd, and Aditazz Inc. Dr. Singh is also a Consulting Professor in the School of Medicine at Stanford University and is the Lead Director on Board of Directors of Max Healthcare based in New Delhi, India. Prior to joining Artiman, Dr. Singh was the President and CEO of BioImagene (acquired by Roche in 2010), a Digital Pathology company specializing in Cancer Diagnostics. Before BioImagene, Dr. Singh spent nearly twenty years at Siemens in various roles, most recently as the Chief Executive Officer of the Digital Radiology business of Siemens Healthcare, based in Germany. From 2001 to 2006, he was the President and CEO of the Oncology Care Systems Group of Siemens, with global headquarters in Concord, California. Between 1996 and 2001, Dr. Singh held the positions of Group Vice President of Siemens e-Health, and Vice President of Siemens Health Services based in Princeton, NJ, where he led the company's Healthcare IT business and Consulting Practice. Before transitioning to these business responsibilities, Dr. Singh spent several years in R&D and academia. From 1989 to 1995, he was at Siemens Corporate Research in Princeton, responsible for research in the areas of artificial intelligence, robotics, computer vision, and image analysis. During this time, he concurrently served on the faculty at Princeton University. Dr. Singh holds a Ph.D. in Computer Science from Columbia University, a master's degree in Computer Engineering from Syracuse University and a bachelor's degree in Electrical Engineering from Banaras Hindu University, India. Dr. Singh is an active speaker in the Life Sciences, Information Technology, and Entrepreneurship communities. He has published two books and numerous refereed articles, and holds five patents.